Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/14/2018 |
| Start Date: | September 2005 |
| End Date: | June 2017 |
The proposed endpoints of the study would be: comparative use of piperacillin versus broader
spectrum agents (e.g., piperacillin/tazobactam, etc.) [measured as defined daily doses per
1000 patient days]; physician acceptance of piperacillin as part of a streamlining program
[measured as successful occurrences of the use of piperacillin as streamlining therapy];
changes in susceptibility patterns of broad spectrum antibiotics [measured as % Gram negative
bacilli susceptible to each of the commonly used broad spectrum antibiotics]; and outcome of
patients treated with streamlined therapy.
spectrum agents (e.g., piperacillin/tazobactam, etc.) [measured as defined daily doses per
1000 patient days]; physician acceptance of piperacillin as part of a streamlining program
[measured as successful occurrences of the use of piperacillin as streamlining therapy];
changes in susceptibility patterns of broad spectrum antibiotics [measured as % Gram negative
bacilli susceptible to each of the commonly used broad spectrum antibiotics]; and outcome of
patients treated with streamlined therapy.
The following variables will be followed: time and location of positive cultures, underlying
diseases and severity of illness, recent immunomodulative therapies, physical exam findings,
laboratory and radiographical data, antimicrobial usage, microbiological data and resistance
patterns, choice of antibiotics once organism is identified, suspected source of infection,
bacteriological outcomes, laboratory results, demographic information, medications, clinical
outcome, gender, height, weight, ethnicity, and past medical history.
diseases and severity of illness, recent immunomodulative therapies, physical exam findings,
laboratory and radiographical data, antimicrobial usage, microbiological data and resistance
patterns, choice of antibiotics once organism is identified, suspected source of infection,
bacteriological outcomes, laboratory results, demographic information, medications, clinical
outcome, gender, height, weight, ethnicity, and past medical history.
Inclusion Criteria:
- Patients with Gram negative infections treated with piperacillin/tazobactam and/or
piperacillin
We found this trial at
1
site
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
Click here to add this to my saved trials
